TY - JOUR
AU - 
TI - Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
JF - Annals of Oncology
DO - 10.1093/annonc/mdi310
DA - 2005-10-01
UR - https://www.deepdyve.com/lp/unpaywall/phase-i-study-to-determine-the-safety-and-pharmacokinetics-of-the-GUmLEn8v7Z
DP - DeepDyve
ER -